Bank of America’s Seelos Therapeutics, Inc. Common Stock SEEL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-32
| Closed | -$120 | – | 8580 |
|
|
2024
Q3 | $120 | Buy |
32
+2
| +7% | +$11 | ﹤0.01% | 7681 |
|
|
2024
Q2 | $282 | Buy |
30
+1
| +3% | +$34 | ﹤0.01% | 7483 |
|
|
2024
Q1 | $2.22K | Hold |
29
| – | – | ﹤0.01% | 7116 |
|
|
2023
Q4 | $5.22K | Buy |
29
+28
| +2,800% | +$13.8K | ﹤0.01% | 7004 |
|
|
2023
Q3 | $590 | Hold |
1
| – | – | ﹤0.01% | 7297 |
|
|
2023
Q2 | $4.99K | Hold |
1
| – | – | ﹤0.01% | 6994 |
|
|
2023
Q1 | $2.71K | Hold |
1
| – | – | ﹤0.01% | 7176 |
|
|
2022
Q4 | $1.43K | Hold |
1
| – | – | ﹤0.01% | 7290 |
|
|
2022
Q3 | $3K | Sell |
1
-37
| -97% | -$145K | ﹤0.01% | 7531 |
|
|
2022
Q2 | $98K | Sell |
38
-91
| -71% | -$237K | ﹤0.01% | 6483 |
|
|
2022
Q1 | $416K | Buy |
129
+100
| +345% | +$430K | ﹤0.01% | 5962 |
|
|
2021
Q4 | $183K | Buy |
29
+27
| +1,350% | +$207K | ﹤0.01% | 6549 |
|
|
2021
Q3 | $15K | Sell |
2
-21
| -91% | -$180K | ﹤0.01% | 7479 |
|
|
2021
Q2 | $232K | Buy |
23
+4
| +21% | +$65.7K | ﹤0.01% | 5993 |
|
|
2021
Q1 | $366K | Buy |
+19
| New | +$222K | ﹤0.01% | 5618 |
|
|
2020
Q3 | – | Hold |
0
| – | – | – | 7242 |
|
|
2020
Q2 | – | Hold |
0
| – | – | – | 7187 |
|
|
2019
Q3 | – | Hold |
0
| – | – | – | 7573 |
|
|
2019
Q2 | – | Hold |
0
| – | – | – | 7467 |
|
|
2019
Q1 | – | Hold |
0
| – | – | – | 7478 |
|
|
2018
Q3 | – | Hold |
0
| – | – | – | 7519 |
|
|
2018
Q2 | – | Hold |
0
| – | – | – | 7381 |
|
|
2017
Q3 | – | Hold |
0
| – | -$1K | – | 7329 |
|
|
2017
Q2 | – | Hold |
0
| – | – | – | 6847 |
|
|
2017
Q1 | – | Hold |
0
| – | – | – | 7286 |
|
|
2016
Q4 | – | Hold |
0
| – | – | – | 6936 |
|
|
2016
Q3 | – | Hold |
0
| – | – | – | 6850 |
|
|
2016
Q2 | – | Hold |
0
| – | – | – | 6464 |
|
|
2016
Q1 | – | Hold |
0
| – | – | – | 6255 |
|
|
2015
Q4 | – | Hold |
0
| – | – | – | 6297 |
|
|
2015
Q3 | – | Hold |
0
| – | – | – | 6049 |
|
|
2015
Q2 | – | Hold |
0
| – | – | – | 5998 |
|
|
2015
Q1 | – | Hold |
0
| – | – | – | 5661 |
|
|
2014
Q4 | – | Hold |
0
| – | – | – | 6662 |
|
|
2014
Q2 | – | Hold |
0
| – | -$2K | – | 8255 |
|
|
2014
Q1 | – | Hold |
0
| – | – | – | 7548 |
|
|
2013
Q4 | – | Hold |
0
| – | – | – | 7583 |
|
|
2013
Q3 | – | Hold |
0
| – | – | – | 7643 |
|
|
2013
Q2 | – | Hold |
0
| – | – | – | 7526 |
|
Other funds holding SEEL
Bank of America's SEEL Position: Q4 2024 in Review
Bank of America sold out of Seelos Therapeutics, Inc. Common Stock (SEEL) in Q4 2024, closing a stake of 32 shares — an estimated $120 sold.
Bank of America first reported a position in SEEL in Q1 2021 and held it in 15 quarters. The position peaked at $416K in Q1 2022. 2 funds tracked by Wall St. Rank hold SEEL as of Q4 2024.
- Bank of America reported no remaining Seelos Therapeutics, Inc. Common Stock position as of Q4 2024 after selling out during the quarter.
- Bank of America sold 32 Seelos Therapeutics, Inc. Common Stock shares in Q4 2024, an estimated $120.
- Bank of America first reported a position in Seelos Therapeutics, Inc. Common Stock in Q1 2021 and held it in 15 quarters.
- Bank of America's Seelos Therapeutics, Inc. Common Stock position peaked at $416K in Q1 2022.
- 2 funds tracked by Wall St. Rank held Seelos Therapeutics, Inc. Common Stock as of Q4 2024.
Based on Bank of America's 13F filing for Q4 2024, filed 14 Feb 2025.